iiinova — where your digital self keeps evolving

Cancer Heterogeneity and Plasticity @chp-pivot.bsky.social · 01/09/2026

📘 CHP Archive Spotlight #18 Review (2026) | Das et al. 🏛️ UC Santa Cruz How does breast cancer evade immunity? HR+, HER2+ & TNBC have distinct immune ecosystems—yet converge on shared mechanisms of immune escape. 🔗 doi.org/10.47248/chp2603010001 #BreastCancer #CancerImmunology

doi.org

The Trojan Horse Within: Mechanisms of Immune Evasion in Breast Cancer

121

Cancer Heterogeneity and Plasticity @chp-pivot.bsky.social · 09/04/2026

📢 Call for Papers — CHP Special Issue Cancer evolves. Tumors adapt. Resistance emerges. Therapies fail. 📘 Molecular Understanding & Therapeutic Targeting of Cancer Heterogeneity and Plasticity 💡 OA | No fees 📅 Apr 30, 2026 (priority; open after) 🔗 www.pivotscipub.com/chp #CancerResearch

Cartoon showing cancer plasticity (cells escaping therapy by changing) and heterogeneity (diverse tumor cell populations), emphasizing therapy resistance and the need for multiple strategies; includes call for papers for CHP special issue (deadline April 30, 2026).

021

Cancer Heterogeneity and Plasticity @chp-pivot.bsky.social · 09/04/2026

📘 CHP Archive Spotlight #12 Original Research (2026) | Wu et al. YAP1 depletion in gastric cancer peritoneal metastases (GCPM) induces compensatory TAZ activation, sustaining tumor progression and metastasis. Reveals adaptive oncogenic signaling via the YAP1–TAZ axis www.pivotscipub.com/chp/3/1/0004

Graphical abstract illustrating that in gastric cancer peritoneal metastases, YAP1 and TAZ are upregulated and act with TEAD transcription factors. Inhibition of YAP1 alone leads to compensatory upregulation of TAZ, which forms a transcriptional complex with TEAD4 and AP-1 (c-JUN/FOSB) to drive expression of oncogenic genes such as SOX9, BIRC5, CTGF, and CYR61. In contrast, co-targeting both YAP1 and TAZ suppresses this transcriptional program and reduces tumor-promoting activity.

131

Cancer Heterogeneity and Plasticity @chp-pivot.bsky.social · 06/03/2026

📘 CHP Archive Spotlight #11 Review (2026) | Rasouli et al. HPV-driven cancers show viral integration, genomic instability, and immune escape. This review examines how HPV heterogeneity fuels therapy resistance and highlights combination therapies. 🔗 doi.org/10.47248/chp... #HPV

Graphical overview of HPV-associated cancer progression and treatment strategies. HPV infection initiates carcinogenesis through E6 and E7 oncoproteins disrupting p53 and Rb, causing genomic instability. Viral genome integration creates molecular heterogeneity leading to increased malignancy, immune evasion, and therapy resistance. Combination therapies—including chemotherapy, radiotherapy, immunotherapy, vaccines, and targeted agents—aim to overcome heterogeneity and improve treatment response.

111

Cancer Heterogeneity and Plasticity @chp-pivot.bsky.social · 03/03/2026

📘 CHP Archive Spotlight #10 Review (2024) | Markl et al. Cancer is not only molecular — it is physical. Tumors reflect: • Stiffness & ECM remodeling • Cell mechanics • Electrical/thermal states • Solid stress Biophysics shapes heterogeneity. 🔗 doi.org/10.47248/chp... #TumorBiophysics #Mechanobiology

Graphical abstract divided into two halves labeled “Physical” and “Biological,” centered around a large cancer cell illustration.
Left (Physical properties):
Mechanical factors such as ECM stiffness and cell viscosity increase during tumor progression. Diagrams illustrate low, mid, and high electrical frequencies (impedance profiling), along with thermal gradients and solid stress within the tumor microenvironment.
Right (Biological consequences):
Physical properties are linked to cancer stem cell enrichment, stemness, metastatic potential, and therapy resistance. Icons show a stem cell cluster, metastatic cell invasion through epithelial layers, radiation and drug resistance, and immune interactions.
The figure emphasizes that tumor physical parameters and biological hallmarks are interconnected and mutually reinforcing, contributing to heterogeneity and clinical outcomes.

111

Cancer Heterogeneity and Plasticity @chp-pivot.bsky.social · 03/03/2026

📘 CHP Archive Spotlight #09 Review (2024) | Balk & Goodrich From development to cancer progression, phenotypic plasticity shapes cell fate. This review dissects the molecular drivers linking homeostasis to therapy resistance. 🔗 doi.org/10.47248/chp... #PhenotypicPlasticity #Epigenetics

Illustrated schematic showing phenotypic plasticity across multiple organs in normal homeostasis and injury contexts. A central human figure is surrounded by circular panels depicting:
• Lung: Alveolar type II (AT2) cells transitioning to AT1 cells after injury.
• Intestine: Crypt base columnar (CBC) stem cells and Paneth cells interacting within the intestinal niche.
• Pancreas: α and β islet cells with bidirectional plasticity under stress.
• Liver: Hepatocytes and biliary epithelial cells (BECs) showing lineage interconversion.
• Skin: Keratinocytes, fibroblasts, immune cells, and adipocytes participating in wound repair and microenvironmental remodeling.
Arrows indicate bidirectional transitions and injury-induced state changes, emphasizing that phenotypic plasticity is a conserved mechanism in tissue maintenance and regeneration.

121

Cancer Heterogeneity and Plasticity @chp-pivot.bsky.social · 01/03/2026

📘 CHP Archive Spotlight #08 Original Research (2024) | Lim et al. TFAP4 directly reactivates TERT in non-HBV HCC — independent of promoter mutation. CTCF → TFAP4 → TERT axis drives telomerase activation, especially in alcohol-related tumors. 🔗 doi.org/10.47248/chp... #HCC #TERT #Telomerase

Schematic model of telomerase reactivation in non-HBV-associated hepatocellular carcinoma. CTCF binds to the TFAP4 promoter and increases TFAP4 expression. TFAP4 then binds directly to the TERT promoter, enhancing TERT mRNA transcription. Increased TERT expression leads to elevated telomerase activity and stabilization of telomeres. Ethanol exposure further upregulates TFAP4 and TERT in non-HBV HCC cells, while this regulatory pathway appears limited in HBV-associated HCC.

121

Cancer Heterogeneity and Plasticity @chp-pivot.bsky.social · 28/02/2026

📘 CHP Archive Spotlight #07 Review (2024) | Her et al. How do noncoding RNAs drive cancer plasticity? miRNAs, lncRNAs, circRNAs & tRNA fragments regulate stemness, EMT, epigenetics & therapy resistance — with emerging roles as biomarkers & targets. 🔗 doi.org/10.47248/chp... #ncRNA #CancerStemCells

Schematic overview of noncoding RNA functions in cancer cell plasticity. The figure is organized by RNA type: miRNAs regulate pluripotency inhibition, translational repression, mRNA degradation, EMT transition, cancer stem cell initiation, and metastasis; lncRNAs modulate epigenetic regulation, transcription, signaling pathways, chromatin architecture, alternative splicing, and dedifferentiation; circRNAs function as miRNA sponges, regulate transcription, interact with RNA-binding proteins, and influence self-renewal and apoptosis; tRNAs and tRNA-derived fragments regulate translation, mRNA stability, mitochondrial homeostasis, metabolic reprogramming, and hormone-dependent signaling.

Illustration of therapeutic strategies targeting noncoding RNAs in cancer. Approaches include synthetic miRNA mimics and lentiviral delivery for oncogene suppression, antisense oligonucleotides and RNA sponges for tumor suppressor restoration, CRISPR-based activation or repression of lncRNAs, synthetic circRNA sponges and Cas13-mediated cleavage, siRNA-loaded nanoparticles, and inhibition of tRNA methyltransferases to block translation and tumor growth.

051

Cancer Heterogeneity and Plasticity @chp-pivot.bsky.social · 28/02/2026

📘 CHP Archive Spotlight #06 Perspective (2024) | Kondo Targeting cancer stem cell heterogeneity & plasticity with a miRNA-dependent AAV system designed to eradicate diverse CSC populations while minimizing side effects. 🔗 doi.org/10.47248/chp... #CancerStemCells #Heterogeneity #AAV

Graphical abstract illustrating cancer stem cell (CSC) heterogeneity driven by genetic, epigenetic, and environmental factors, and a proposed miRNA-dependent AAV strategy selectively eradicating heterogeneous CSCs to prevent recurrence.

031

Cancer Heterogeneity and Plasticity @chp-pivot.bsky.social · 27/02/2026

📘 CHP Archive Spotlight #05 Perspective (2024) | Jamroze, Liu & Tang AR signaling inhibitors induce lineage plasticity in prostate cancer, promoting stem-like, mesenchymal & neural states driving CRPC & NEPC progression. 🔗 doi.org/10.47248/chp... #LineagePlasticity #CRPC #CancerStemCells

Graphical abstract illustrating ARSI-induced lineage plasticity in prostate cancer. Androgen receptor signaling inhibition promotes transition from prostate adenocarcinoma (PRAD) to aggressive CRPC variants with increased mesenchymal, basal, stem-like, and neural cell states, highlighting reversibility and tumor heterogeneity.

011

Cancer Heterogeneity and Plasticity @chp-pivot.bsky.social · 26/02/2026

📘 CHP Archive Spotlight #04 Review (2024) | Chen et al. Linking phenotype ↔ genotype at single-cell resolution. Reviews tools for isolating and profiling individual cells — key to understanding plasticity, metastasis & therapy resistance. 🔗 doi.org/10.47248/chp... #SingleCell #CancerHeterogeneity

Graphical abstract illustrating single-cell isolation and labeling techniques linking cell phenotype to genotype. Methods such as robotic aspiration, laser detachment, microraft arrays, optical tweezers, droplet microfluidics, and spatial omics enable selective retrieval and molecular analysis of individual cells to study cancer heterogeneity.

021

Cancer Heterogeneity and Plasticity @chp-pivot.bsky.social · 26/02/2026

📘 CHP Archive Spotlight #02 Original Research (2024) | Wong et al. 📢 New mechanistic insight in CRC liver metastasis: Cancer cells upregulate SMLR1 to engage immunosuppressive TAMs, reshaping the liver niche. 🔗 www.pivotscipub.com/chp/1/1/0003... #ColorectalCancer #TumorMicroenvironment

Graphical abstract illustrating colorectal cancer liver metastasis. Cancer cells in the colon metastasize to the liver, where they upregulate SMLR1. SMLR1 interacts with macrophage receptors MRC1 (CD206) and SIGLEC1 (CD169), promoting tumor–macrophage interactions within the liver microenvironment. Legend indicates cancer cells (green), macrophages (beige), and molecular interactions.

121

Cancer Heterogeneity and Plasticity @chp-pivot.bsky.social · 26/02/2026

📘 CHP Archive Spotlight #01 Inaugural Editorial (2024) EIC Dean Tang outlines CHP’s mission: dissecting how cancer heterogeneity, plasticity & tumor microenvironment interactions drive therapy resistance, metastasis & recurrence. 📖 CHP 2024;1(1):0001 🔗 doi.org/10.47248/chp... #TumorPlasticity

021

Reposted by Cancer Heterogeneity and Plasticity

Shaheen Sikandar @ssikandar.bsky.social · 09/12/2025

📢 We review the mechanisms of immune evasion in breast cancer, focusing on how cellular plasticity and the tumor immune microenvironment cooperate to suppress detection. 🧬 @chp-pivot.bsky.social www.pivotscipub.com/chp/3/1/0001... #breastcancer #ImmuneEvasion #TumorMicroenvironment #CellPlasticity

pivotscipub.com

The Trojan Horse Within: Mechanisms of Immune Evasion in Breast Cancer

041

Reposted by Cancer Heterogeneity and Plasticity

Juan Carlos López-Gil @juancarloslpz13.bsky.social · 17/06/2025

Fresh from the oven!! Our latest review published in @chp-pivot.bsky.social about the origin of PDAC CSCs and their inner and outer determinants by Diego Navarro and myself. A little bit of inflammation, a little bit of CIN, tons of stemness!! Enjoy!! www.pivotscipub.com/chp/2/2/0010

031

Cancer Heterogeneity and Plasticity @chp-pivot.bsky.social · 20/02/2026

CHP focuses on cancer cell states, lineage plasticity, and tumor microenvironment dynamics. Since 2024, we’ve published research and reviews advancing this area. Explore: www.pivotscipub.com/chp Looking forward to engaging with the cancer plasticity and heterogeneity community here on Bluesky.

Editorial board slide for Cancer Heterogeneity and Plasticity (CHP) listing seven editors with headshots and affiliations across USA, Germany, Japan, China, and Canada, including Dean G. Tang (Roswell Park), Anna Dubrovskа (OncoRay), Toru Kondo (Hokkaido), Jinsong Liu (MD Anderson), Suling Liu (Zhejiang University), Amina Zoubeidi (UBC), and Ping Mu (Yale).

131